Protara Therapeutics (TARA) Current Assets (2013 - 2026)

Protara Therapeutics (TARA) has reported Current Assets for 14 consecutive years, with $140.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Assets rose 10.64% year-over-year to $140.0 million; the TTM figure through Mar 2026 stood at $140.0 million (up 10.64% YoY), while the FY2025 annual figure was $159.5 million, down 7.35% from the prior year.
• Current Assets declined to $140.0 million in Q1 2026 per TARA's latest filing, from $159.5 million in the prior quarter.
• Across five years, Current Assets topped out at $172.2 million in Q4 2024 and bottomed at $57.9 million in Q1 2024.
• Historically, Current Assets has averaged $105.7 million across 5 years, with a median of $94.6 million in 2023.
• On a YoY basis, Current Assets climbed as much as 150.57% in 2024 and fell as far as 38.79% in 2024.
• Protara Therapeutics' Current Assets stood at $86.1 million in 2022, then dropped by 20.25% to $68.7 million in 2023, then jumped by 150.57% to $172.2 million in 2024, then retreated by 7.35% to $159.5 million in 2025, then dropped by 12.23% to $140.0 million in 2026.
• Business Quant data shows TARA's Current Assets at $140.0 million in Q1 2026, $159.5 million in Q4 2025, and $135.6 million in Q3 2025.